Filing Flows › Adma Biologics (ADMA) › Q1 2026
Adma Biologics (ADMA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Adma Biologics (ADMA) reported revenue of $114M for the first quarter 2026 (Q1 2026), -0.3% from a year earlier and -18% from the quarter before. Operating margin was 50.9%, net earnings $45.3M (39.6% of revenue).
Adma Biologics, Q1 2026: revenue $114M (-0.3% year over year), operating margin 50.9%, net earnings $45.3M, operating cash flow $58.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $114M | -18% | -0.3% |
| Gross profit | $80.8M | -9% | +32% |
| Operating profit | $58.3M | -7% | +67% |
| Net earnings | $45.3M | -8% | +68% |
| Operating cash flow | $58.2M | +63% | — |
| Free cash flow | $55.7M | +61% | — |
What changed
Revenue was $114.5M in Q1 2026, roughly flat year over year and down 18% from the previous quarter. ADMABio Manufacturing Segment was the largest line at 99% of revenue. Plasma Collection Centers Segment lost $334K year over year (down 32%), 108% of the total change.
Gross margin was 70.5%, up 17.3 points from Q1 2025. Operating profit was $58.3M, a 50.9% margin (up 20.5 points year over year). Operating expenses fell 14% while revenue was flat. Net earnings were $45.3M, up 68% year over year. The effective tax rate was 20.7%.
Operating cash flow was $58.2M, 129% of net earnings. Non-cash charges added back $1.8M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items added $4.8M. Capital expenditures of $2.5M left free cash flow of $55.7M.
Questions
What was Adma Biologics' revenue in the first quarter 2026?
Adma Biologics (ADMA) reported revenue of $114M for the first quarter 2026 (Q1 2026), -0.3% from a year earlier and -18% from the quarter before.
Was Adma Biologics profitable in the first quarter 2026?
Operating profit was $58.3M (50.9% of revenue) and net earnings $45.3M.
Source: Adma Biologics 10-Q on SEC EDGAR.